Topical Imiquimod for Periocular Lentigo Maligna

被引:22
|
作者
Demirci, Hakan [1 ]
Shields, Carol L. [1 ]
Bianciotto, Carlos G. [1 ]
Shields, Jerry A. [1 ]
机构
[1] Thomas Jefferson Univ, Wills Eye Inst, Ocular Oncol Serv, Philadelphia, PA 19107 USA
关键词
MELANOMA IN-SITU; BASAL-CELL CARCINOMA; CUTANEOUS MELANOMA; 5-PERCENT CREAM; INVASIVE MELANOMA; MANAGEMENT; EXCISION; RECURRENCE; SKIN;
D O I
10.1016/j.ophtha.2010.03.049
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To evaluate the efficacy of topical imiquimod 5%, a local immune response modifier, in the treatment of periocular lentigo maligna. Design: Retrospective, interventional case series. Participants: Five consecutive patients with biopsy-proven periocular lentigo maligna. Methods: Periocular lentigo maligna was treated with topical imiquimod 5%. The clinical features, treatment schedule, response to treatment, and complications were analyzed retrospectively. Main Outcome Measures: Response to treatment and complications. Results: The mean patient age was 73 years. The anatomic location of lentigo maligna was the medial canthal area in 2 patients, the lateral canthal area in 1 patient, and the lower eyelid in 2 patients. Topical imiquimod 5% was used for 5 days per week in 3 patients and for 7 days per week in 2 patients. The medication was placed only on the skin and not the globe. The mean duration of treatment was 9 months (range, 1-14 months). Lentigo maligna partially resolved in 3 patients and completely resolved in 2 patients. The most common side effects included localized erythema and discomfort (n = 4), swelling (n = 3), and cutaneous excoriation (n = 2). There were no patients with toxicity to the conjunctiva, cornea, or globe. Treatment was discontinued in 2 patients (one temporarily and the other permanently) because of intolerable local side effects of discomfort, redness, swelling, and cutaneous excoriation. There was no recurrence of lentigo maligna in those with complete or partial response (mean follow-up, 20 months). Conclusions: Periocular lentigo maligna seems to respond to topical imiquimod 5% treatment. Topical imiquimod 5% treatment for periocular lentigo melanoma deserves further study. Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2010;117:2424-2429 (C) 2010 by the American Academy of Ophthalmology.
引用
收藏
页码:2424 / 2429
页数:6
相关论文
共 50 条
  • [31] Lentigo maligna melanoma treated with Imiquimod
    Alomar, A.
    Dalmau, Joan
    ARCHIVES OF DERMATOLOGICAL RESEARCH, 2007, 299 (5-6) : 284 - 284
  • [32] Characterization of the cellular infiltrate during successful topical treatment of lentigo maligna with imiquimod
    Michalopoulos, P
    Yawalkar, N
    Brönnimann, M
    Kappeler, A
    Braathen, LR
    BRITISH JOURNAL OF DERMATOLOGY, 2004, 151 (04) : 903 - 906
  • [33] Imiquimod: a novel treatment for lentigo maligna
    Ahmed, I
    Berth-Jones, J
    BRITISH JOURNAL OF DERMATOLOGY, 2000, 143 (04) : 843 - 845
  • [34] Observational Study of Topical Imiquimod Immunotherapy in the Treatment of Diffi cult Lentigo Maligna
    Craythorne, E. E.
    Lawrence, C. M.
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2008, 2 : 551 - 554
  • [35] Periocular lentigo maligna successfully treated with immunocryosurgery
    Oro-Ayude, Marcos
    Gonzalez-Sixto, Beatriz
    Faraldo-Lorenzo, Jose Manuel
    Feal, Carlos
    Florez, Angeles
    DERMATOLOGIC THERAPY, 2021, 34 (01)
  • [36] Recurrence of Lentigo Maligna and Development of Invasive Melanoma after Treatment of Lentigo Maligna with Imiquimod
    Woodmansee, Courtney S.
    McCall, Michael W.
    DERMATOLOGIC SURGERY, 2009, 35 (08) : 1286 - 1289
  • [37] Efficacy of imiquimod in the management of lentigo maligna.
    Dreno, Brigitte
    Dinulescu, Monica
    NGuyen, Jean-Michel
    Maillard, Heve
    Le Duff, Florence
    Machet, Laurent
    Beylot-Barry, Marie
    Legoupil, Delphine
    Wierzbicka-Hainaut, Ewa
    Bedane, Christophe
    Leccia, Marie Therese
    Debarbieux, Sebastien
    Meyer, Nicolas
    Monestier, Sandrine
    Bens, Guido
    Denis, Marc G.
    Bossard, Celine
    Vergier, Beatrice
    Khammari, Amir
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [38] Combination Topical Therapy for Conjunctival Primary Acquired Melanosis With Atypia and Periocular Lentigo Maligna
    Bratton, Emily M.
    Knutsen-Larson, Siri
    Durairaj, Vikram D.
    Gregory, Darren G.
    Mellette, J. Ramsey
    CORNEA, 2015, 34 (01) : 90 - 93
  • [39] Topical Treatment of Lentigo Maligna
    Buergler, C.
    Gadaldi, K.
    Hunger, R. E.
    AKTUELLE DERMATOLOGIE, 2016, 42 (12) : 507 - 509
  • [40] Effect of topical imiquimod as primary treatment for lentigo maligna: the LIMIT-1 study
    Marsden, J. R.
    Fox, R.
    Boota, N. M.
    Cook, M.
    Wheatley, K.
    Billingham, L. J.
    Steven, N. M.
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 176 (05) : 1148 - 1154